The looming health crisis on the horizon
Welcome to PharmaVoice's LinkedIn newsletter, Industry Pulse. Today we’re examining the obstacles and advances in the mental health treatment space. For more insights every day, sign up here to receive our stories on the biggest trends and voices in the life sciences industry by email every morning.
A cascading chronic health crisis could be looming. That’s the takeaway from a study published last week by the European Journal of Preventive Cardiology, which found that younger adults with mental illness may be more at risk for other severe health conditions.
About 80% of participants in the study, which was based on health data for Korean adults in their 20s and 30s, experienced some mental health condition, ranging from depression and anxiety to PTSD, schizophrenia, insomnia and more. And of those, 58% were more likely to have a heart attack and 42% were more likely to have a stroke.
Because these coronary diseases historically have been rare for people under age 40, the study raises questions about whether increasing rates of mental illness, particularly in younger generations, could lead to greater incidence of other health conditions down the road.
With one in four adults who experience mental illness reporting an unmet need for treatment, better drugs are a major piece of the puzzle to solving the crisis.
In observance of Mental Health Awareness Month, here's a look at some of the obstacles and recent advances in the effort to develop better treatments for mental conditions.
Depression has long been treated chronically — Sage wants to change that
Sage Therapeutics is planning a launch of its newest med, and its chief business officer explains how it could upend the way depression has long been treated.
All eyes turn to Karuna as it aims for an approval of a would-be blockbuster
In the red-hot race for new schizophrenia treatments, Karuna Therapeutics is close to an FDA submission.
Recommended by LinkedIn
Why are there gaps in mental healthcare? Often it’s flawed trial methodology
Sunovion Pharmaceuticals has developed a more precise way to track symptoms that could be broadly adopted across the industry.
Compass has the most advanced psychedelic drug in trials — but it needs a new approach to rollout to make it a success
The company’s CEO, Kabir Nath, discusses potential roadblocks to commercialization that await its psilocybin treatment for depression.
A combo of precision meds and diagnostics could disrupt mental healthcare
HMNC Brain Health, a clinical-stage company, is leveraging cutting-edge tech to offer a new approach to mental health challenges.
This is just a sampling of PharmaVoice’s coverage. For more insights into the biggest trends and voices swaying the life sciences industry, be sure to check out our daily newsletter.
Founder and Principal @ MindMastery Labs Creating Space for Growth | Learning & Development | Sales Training | Recruitment Training | Process Development | Consultant
1yGreat insight, highlighting that it's crucial that we address the potential health crisis associated with mental illness in younger adults, and its cascading effects. The findings underscore the importance of developing better treatments for mental conditions, as they may have a significant impact on overall health.